Filing Details
- Accession Number:
- 0001209191-15-034737
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2015-04-16 21:25:42
- Reporting Period:
- 2014-12-19
- Filing Date:
- 2015-04-16
- Accepted Time:
- 2015-04-16 21:25:42
- Original Submission Date:
- 2014-12-22
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1513818 | Versartis Inc. | VSAR | Pharmaceutical Preparations (2834) | 244106690 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1601948 | L Jeffrey Cleland | C/O Versartis, Inc. 4200 Bohannon Drive, Suite 250 Menlo Park CA 94025 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2014-11-14 | 1,900 | $0.00 | 141,388 | No | 5 | G | Direct | |
| Common Stock | Disposition | 2014-12-19 | 20 | $20.00 | 141,368 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2014-12-22 | 2,110 | $20.54 | 139,258 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2014-12-22 | 5,870 | $21.36 | 133,388 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 5 | G | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Includes 892 shares purchased on 11/14/14 pursuant to the issuer's employee stock purchase plan.
- Shares sold pursuant to a 10b5-1 trading plan.
- The shares were sold at prices ranging from $20.04 to $21.03. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The shares were sold at prices ranging from $21.06 to $21.87. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
Billionaire Hedge Funds
